<DOC>
	<DOCNO>NCT00249990</DOCNO>
	<brief_summary>The purpose study : 1.1 To determine efficacy liposomal 9-Nitro-20 ( S ) -Camptothecin ( L9NC ) administer aerosolization patient metastatic endometrial cancer . 1.2 To determine toxicity profile L9NC administer aerosolization 5 consecutive day per week X 8 week , every 10 week . 1.3 To perform pharmacology study L9NC plasma lung aerosolization . A specific protocol write part .</brief_summary>
	<brief_title>Phase II Study Aerosolized Liposomal 9-Nitro-20 ( S ) - Camptothecin ( L9NC )</brief_title>
	<detailed_description>RATIONALE : Camptothecin ( CPT ) plant alkaloid isolate Camptotheca acuminata 1966 . As topoisomerase I inhibitor , powerful anticancer property use clinically treatment variety cancer . It possess significant toxicity , especially involve bone marrow gastrointestinal tract limit use . Derivatives 20- ( S ) -camptothecin make increase aqueous solubility compound and/or modify A-ring increase membrane association . The 9-nitrocamptothecin ( 9-NC ) derivative use study insoluble water , demonstrate potent antitumor effect mice antitumor effect human . However , therapeutic index low . In order increase therapeutic index , liposomal formulation develop , administer aerosol . In human , dose 0.52 mg/m2/day 5 day per week eight 8 week 10 week course well tolerated Phase I study . Partial response note patient endometrial cancer . The recommended starting dose L9NC Phase II study 0.52 mg/m2/day administer day aerosol ( mouth-only breathing ) five consecutive day per week x 8 week follow 2 week rest . Courses 10 week . This dose correspond approximately 1/6 MTD oral 9-NC administer untreated cancer patient .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion : All patient , 18 year age old , metastatic and/or recurrent endometrial cancer mixed mesenchymal malignant tumor whose epithelial component recur , fail standard chemotherapy hormonal regimen disease refuse recommend standard chemotherapy eligible . Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients must know symptomatic respiratory disease cancer , must pulmonary function test equal &gt; 50 % forced expiratory volume 1 second ( FEV1 ) , &gt; 50 % FEV1/forced vital capacity ( FVC ) , &gt; 50 % total lung capacity ( TLC ) , &gt; 50 % diffusing capacity lung carbon monoxide ( DLCO ) predict value . Patients symptomatic brain metastasis exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial . Any criterion borderline may lead ineligibility review principal investigator ( PI ) , may override eligibility criterion , receive sponsor agreement , entry study deem potentially benefit patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Uterus</keyword>
	<keyword>Recurrent disease</keyword>
	<keyword>Treatment</keyword>
	<keyword>9-Nitrocamptothecin</keyword>
	<keyword>Endometrium</keyword>
</DOC>